Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunotherapy
University of Texas publishes research in immunotherapy
July 30th, 2008
According to recent research published in the journal Expert Opinion on Biological Therapy, "Patients with metastatic melanoma are immunosuppressed by the growing tumor. Allovectin-7 therapy is a form of active immunotherapy that aims at immunization of the host with substances designed to elicit an immune reaction that will eliminate or slow down the growth and spread of the cancer." "to describe the rationale for immunotherapy with Allovectin-7 and assess its safety profile and efficacy based on the results of completed melanoma clinical trials. we reviewed both the published medical literature and the results of trials pending publication," wrote A.Y. Bedikian...
Source: Vaccine Weekly (2008-07-30)
|
